

## Key Takeaways

- Global equities were up in February, despite expectations of higher peak interest rates following resilient economic data from a number of developed economies.
- Asian equities were weaker over the month, with some profit taking after the recent rally in China, in addition to rising geopolitical tensions.
- The Antipodes Global Fund performed in-line with the benchmark over the month, and remains meaningfully ahead over 12 months.

## Commentary\*

Global equities were down in USD over the month, however higher in AUD/NZD due to exchange rate impacts (+1.5%), with information technology, industrials and financials outperforming and materials, utilities and communication services underperformed.

US equities outperformed broader global equities (+1.9%) with the month beginning with expectations that central banks were nearing the end of the hiking cycle. Resilient economic data, however, caused this narrative to shift, pricing in higher peak interest rates across developed economies, with yields moving higher and equities moving lower. European equities outperformed (+3.8%) despite evidence of strong macroeconomic data and repricing of future central bank rate decisions. The region benefitted from further falls in gas prices, discussions of decarbonisation funding stimulus and flow-on benefits from re-opening in China.

Asian equities underperformed broader markets over the month (-1.5%). Chinese equities were down (-3.7%) as a result of increasing geopolitical tensions and some profit taking after the recent rally. Japanese equities underperformed (+0.5%) as a surprise candidate emerged to lead the Bank of Japan, with the view that monetary policy tightening may be increasingly likely.

Elsewhere, Brent Crude (-2.3% in USD) was lower, Gold (-5.3%) was weak, whilst the US Dollar (+2.7%) was stronger.

Key contributors included:

- Internet/Software - DM cluster, namely Meta Platforms with the platform exceeding analyst estimates in the company's fourth-quarter earnings. CEO Mark

Zuckerberg alluded to further efficiencies which may include streamlining Meta's workforce and further cost cutting.

- Consumer Cyclical – DM cluster, including UniCredit which continued higher after posting a record quarterly and pledging to return €5.25 billion in capital to shareholders.
- Healthcare cluster, notably Seagen after the biopharmaceutical company reported 2022 full-year and fourth-quarter results exceeding estimates. Further, the company provided CY23 guidance indicating a revenue uplift of 9.5% on 2022. Later in the month, Seagen surged on reports Pfizer is potentially looking to acquire the company.
- Industrials cluster, including Stellantis NV after the automaker posted a better-than-expected annual profit, leading to the announcement of a buyback.

Key detractors included:

- Consumer Cyclical – Asia/EM cluster including Country Garden Services and Ping An Insurance which saw profit taking after a strong rally to start the year. Country Garden Services was also impacted by weaker January property data as a result of the Chinese New Year period.
- Internet/Software – Asia/EM, including Alibaba with the platform selling off amid rising geopolitical tensions, led by offshore sellers.
- Tail Risk cluster, including Barrick Gold after reporting mixed fourth quarter earnings with a beat on earnings-per-share however a miss on revenue expectations. The miner also announced a buyback of up to US\$1bn worth of stock over the next 12 months.

\* Illustrative only and not a recommendation to buy or sell any particular security.

## Net performance (%)

	Fund	Benchmark	Difference
1 month	1.5	1.5	0.0
3 month	6.8	-0.7	7.5
Year to date	6.7	4.7	2.0
1 year	6.0	-1.3	7.3
3 year p.a.	6.4	7.2	-0.8
5 year p.a.	5.5	8.9	-3.5
Inception p.a.	8.5	9.1	-0.6

Past performance is not a reliable indicator of future performance. Returns are quoted in AUD and net of applicable fees, costs and taxes. All p.a. returns are annualised.

## Performance & risk summary<sup>1</sup>


Average net exposure	65.3%
Upside capture ratio	71
Downside capture ratio	44
Portfolio standard deviation	9.1%
Benchmark standard deviation	11.1%
Sharpe ratio	0.96

## Performance contribution<sup>2</sup> (%)

	1 month
Long	1.1%
Short	0.2%
Currency	0.2%

<sup>2</sup> Based on gross returns in AUD

## Top & bottom sector contribution<sup>2,3</sup> (%)



<sup>3</sup> Antipodes classification

## Fund facts

Characteristics	
Investment manager	Antipodes Partners
Inception date	1 July 2015
Benchmark	MSCI All Country World Next Index in AUD
Management Fee	1.20% p.a.
Performance Fee	15% of net return in excess of benchmark
Risk/Return profile	High
Buy/Sell spread	±0.30%
Minimum Investment	AUD \$25,000
Distribution	Annual, 30 June
Asset value	
Fund AUM	\$2,375m
Strategy AUM	\$4,866m
Unit redemption price	1.7028


<sup>1</sup> All metrics are based on gross of fee returns in AUD terms. The upside/downside capture ratio is the percentage of benchmark performance captured by the fund during months that the benchmark is up/down. Standard deviation is a measure of risk with a smaller figure indicating lower return volatility. The Sharpe ratio measures returns on a risk adjusted basis with a figure > 1 indicating a higher return than the benchmark for the respective levels of return volatility.

Asset allocation<sup>4</sup>

	Equities - Long	Other - Long	Equities - Short	Other - Short
Weight (%)	98.6	-	-28.6	-11.0
Count	73.0	-	48.0	5
Avg. weight (%)	1.4	-	-0.6	-2.2
Top 10 (%)	28.0	-	-16.2	-
Top 30 (%)	62.9	-	-25.3	-

<sup>4</sup> Call (put) options represented as the current option value (delta adjusted exposure)

Sector exposure<sup>4,5</sup> (%)




<sup>5</sup> Antipodes classification

Top 10 equity longs<sup>4</sup> (%)

Name	Country	Weight
Sanofi	France	3.3
TotalEnergies	France	3.2
Siemens	Germany	2.9
Merck	United States	2.8
Oracle	United States	2.7
Meta Platforms	United States	2.7
Frontier Communications	United States	2.7
SAP	Germany	2.7
Baidu	China/HK	2.6
Siemens Energy	Germany	2.5

Currency exposure<sup>4,6</sup> (%)



<sup>6</sup> Where possible, regions, countries and currencies classified on a look through basis

Regional exposure<sup>4,5,6</sup> (%)

Region	Long	Short	Net	Benchmark
<b>North America</b>	<b>36.4</b>	<b>-13.6</b>	<b>22.8</b>	<b>63.5</b>
<b>Western Europe</b>	<b>34.9</b>	<b>-3.5</b>	<b>31.4</b>	<b>16.5</b>
- Eurozone	25.3	-2.4	22.9	8.4
- United Kingdom	6.7	-	6.7	3.7
- Rest Western Europe	2.9	-1.1	1.8	4.4
<b>Developing Asia/EM</b>	<b>18.8</b>	<b>-3.4</b>	<b>15.4</b>	<b>9.5</b>
- China/Hong Kong	14.2	-0.5	13.7	4.6
- India	0.0	-2.9	-2.9	1.4
- Rest Developing Asia/EM	4.5	-	4.5	3.5
<b>Developed Asia</b>	<b>6.7</b>	<b>-1.4</b>	<b>5.2</b>	<b>8.4</b>
- Korea/Taiwan	4.3	-0.5	3.9	2.9
- Japan	2.3	-1.0	1.3	5.4
<b>Oceania</b>	<b>1.9</b>	<b>-3.9</b>	<b>-2.0</b>	<b>2.2</b>
<b>Other equity</b>	<b>0.0</b>	<b>-2.7</b>	<b>-2.7</b>	<b>0.0</b>
<b>Total Equities</b>	<b>98.6</b>	<b>-28.6</b>	<b>70.0</b>	<b>100.0</b>
<b>Other</b>	<b>0.0</b>	<b>-11.0</b>	<b>-</b>	<b>0.0</b>
<b>Cash</b>	<b>1.4</b>	<b>-</b>	<b>-</b>	<b>0.0</b>
<b>Totals</b>	<b>100.0</b>	<b>-39.5</b>	<b>-</b>	<b>100.0</b>

Market cap exposure<sup>4</sup> (%)

Band	Weight	Short	Net
Mega (>\$100b)	35.4	-17.4	18.1
Large (>\$25b <\$100b)	35.7	-4.7	31.0
Medium (>\$5b <\$25b)	21.1	-5.5	15.6
Small (<\$5b)	6.3	-1.0	5.4

## Investment Manager

- Global pragmatic value manager, long only and long-short
- Structured to reinforce alignment between investors and the investment team
- We attempt to take advantage of the market's tendency for irrational extrapolation, identify investments that offer a high margin of safety and build portfolios with a capital preservation focus

## Fund Ratings



## Further information

- ☎ 1300 010 311
- ✉ [invest@antipodespartners.com](mailto:invest@antipodespartners.com)

## Australia Head Office

Antipodes Partners Limited  
Level 35, 60 Margaret St  
Sydney NSW 2000  
Australia

## UK Office

Antipodes Partners Limited  
6th Floor, Nova North  
11 Bressenden Place  
London SW1E 5BY UK

## Disclaimer

This communication is prepared by Antipodes Partners Limited ('Antipodes') (ABN 29 602 042 035, AFSL 481580) as the investment manager of the Antipodes Global Fund (ARSN 087 719 515) ('the Fund'). Pinnacle Fund Services Limited ('PFSL') (ABN 29 082 494 362, AFSL 238371) is the product issuer of the Fund. PFSL is not licensed to provide financial product advice. PFSL is a wholly-owned subsidiary of the Pinnacle Investment Management Group Limited ('Pinnacle') (ABN 22 100 325 184). The Product Disclosure Statement ('PDS') and Target Market Determination ('TMD') of the Fund are available via below links. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund.

Link to [Product Disclosure Statement](#)

Link to [Target Market Determination](#)

For historic TMD's please contact Pinnacle client service Phone 1300 010 311 or Email [service@pinnacleinvestment.com](mailto:service@pinnacleinvestment.com)

This communication is for general information only. It is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is for illustrative purposes only and is not indicative of future performance. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value. Unless otherwise specified, all amounts are in Australian Dollars (AUD).

Whilst Antipodes, PFSL and Pinnacle believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Antipodes, PFSL and Pinnacle disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information. This disclaimer extends to any entity that may distribute this communication.

Any opinions and forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information available as at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future.

Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Antipodes. Pinnacle and its associates may have interests in financial products and may receive fees from companies referred to during this communication.

**Zenith Disclaimer:** The Zenith Investment Partners ('Zenith') (ABN 27 103 132 672, AFSL 226872) rating (assigned Antipodes Global Fund – November 2022) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at [Fund Research Regulatory Guidelines](#).

**Lonsec Disclaimer:** The Lonsec Rating (assigned April 2022) presented in this document is published by Lonsec Research Pty Ltd ('Lonsec') (ABN 11 151 658 561, AFSL 421445). The Rating is limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at <https://www.lonsec.com.au/fund-manager/investment-product-ratings>.

## Fund features

- Objective to achieve absolute returns in excess of the benchmark (after fees) over the investment cycle (typically 3-5 years)
- In the absence of finding securities that meet minimum risk-return criteria, cash may be held
- Equity shorts and currency positions used to take advantage of attractive risk-return opportunities, offset specific long portfolio risks and provide some protection from negative tail risk. Derivatives may also be used to amplify high conviction ideas
- Typical net equity exposure of 50% to 100%; maximum gross exposure of 150% of NAV
- This product is likely to be appropriate for a consumer seeking capital growth to be used as a small allocation within a portfolio where the consumer has a minimum investment timeframe of 5 years, and a high risk/return profile.